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I. INTRODUCTION 
By using adjuvants, quality of vaccines can be enhanced 
that can selectively excite immunoregulatory responses [3]. 
Chemical nature of adjuvants is unpredictable [21]. 
Hundred of materials have been tried as adjuvant and used 
in realistic vaccination for more than 60 years [17.22]. In 
human vaccinations aluminum and calcium phosphate, oil 
emulsions, nanoparticles and molecular assemblies have 
some use [5,12]. AlPO4 and AlOH used as an adjuvant in 
many vaccines licensed by the US Food and Drug 
Administration [16]. Alum is most commonly used 
chemical as adjuvant (such as tetanus toxoids) in human and 
veterinary vaccines also [6,15].  
 
II. MECHANISM 
Adjuvants should be selected for routine use as it may have 
adverse mean of action and alum mechanism is not fully 
understood [4, 15]. However mode of action of alum 
adjuvant can enhance both T helper cell 1 as well as T 
Helper cell 2 cellular response by NLRP3 pathway.6. Alum 
activates caspase-1 and induce secretion of mature 
Interleukin-1β and Interleukin-18 [8].  
  
III. POTENCY 
Potency of adjuvants reliant upon the physio-chemical 
uniqueness and electrostatic forces between adjuvant and 
foreign agent [1]. One study in murine model showed CAP 
is more potent than alum and nano particulate adjuvant of 
CAP would possible to use [3]. While another research 
showed CAP adjuvanticity is lower or equal to alum [2]. If 
number of organisms (e.g; pertusis) present in vaccine is 
less would result in reduced potency [10].  
 
IV. BENEFITS 
Authors conclude that alum is competent to provoke a good 
antibody (Th2) response [6, 14]. Single dose immunization 
with potent alum adsorbed toxoids is possible and booster 
immunization with alum toxoids elicite the IgE [9,19]. In 
vivo purified TT and AlPO4 adjuvant bring out vascular 
permeability-increasing and poisonous effects to 
macrophages [13,18]. CAP is natural constituent of body 
and enhances an insignificant IgE responses [3].  
 
V. LIMITATIONS 
Limitations of alum adjuvants consist of local response, 
augmentation of IgE antibody reaction, incompetence for 
some antigens and failure to boost cell-mediated immune  
(especially cytotoxic T-cell ) responses [14,16]. Aluminium 
salts in vaccines do not cause severe or long lasting 
undesirable effects [7]. Investigation on adjuvants indicates 
that alum can be replace with other adjuvant formulations 
like MF59 emulsion and poly lactide co-glycolide (PLG) 
[20]. One study on  young children showed that vaccination 
with alum caused significantly more local reactions than 
plain vaccines [7]. There is haemolytic effect by Ca-gel 
[18]. 
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